Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Peter Wiesli, Marcus Schories

ABSTRACT

INTRODUCTION: Insulin glargine 300 U/mL (Gla-300, Toujeo®) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). These properties have been shown to translate into an effective HbA1c reduction with the advantage of a lower risk of hypoglycemia in randomized controlled trials of Gla-300 versus Gla-100. In this study, we assessed the effectiveness and safety of Gla-300 under real-world conditions in Switzerland. METHODS: The prospective, observational, open-label, multicenter study TOP-2 explored the effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5-10%) on their previous basal insulin in Germany, Austria, and Switzerland. The primary endpoints were the percentages of patients achieving a fasting plasma glucose (FPG) of ≤ 6.1 mmol/L after 6 and 12 months. Secondary endpoints included changes in HbA1c, FPG, body weight, and insulin dose as well as hypoglycemia incidence and safety. Here we report the results for the Swiss patient cohort after 12 months of treatment with insulin glargine 300 U/mL. RESULTS: The 62 patients (33 men) had a mean age of 65 years, a mean diabetes duration of 14 years, a mean body mass index (BMI) of 31 kg/m2, and were mainly switched from Gla-100 (44%) to Gla-300. The most common concomitant oral anti-diabetes therapy was metformin (65%). The mean individual HbA1c target chosen by the investigators was 7.4%. After 12 months of therapy, Gla-300 significantly reduced mean HbA1c from 8.2% to 7.6% (p < 0.0001). Likewise, Gla-300 significantly reduced mean FPG from 9.1 mmol/L to 7.4 mmol/L (p < 0.0001). At study end, 32% of patients achieved FPG ≤ 6.1 mmol/L, 55% achieved FPG ≤ 7.2 mmol/L , and 57% achieved their individual HbA1c target. Gla-300 was uptitrated to a mean dose of 40 units per day. Symptomatic hypoglycemia incidence after 12 months was low at 9.7% and a rate of 0.23 events per patient year. Body weight remained stable and was not significantly altered during the study. CONCLUSION: Upon switching basaI insulin to Gla-300, overall glucose control significantly improved and glycemic targets were achieved with a low rate of hypoglycemia in T2D patients under real-world conditions in Switzerland. FUNDING: Sanofi-Aventis (Suisse) SA. More... »

PAGES

2325-2334

References to SciGraph publications

Journal

TITLE

Diabetes Therapy

ISSUE

6

VOLUME

9

Author Affiliations

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-018-0518-x

DOI

http://dx.doi.org/10.1007/s13300-018-0518-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107493201

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30302721


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Kantonsspital Frauenfeld", 
          "id": "https://www.grid.ac/institutes/grid.459679.0", 
          "name": [
            "FMH Endokrinologie/Diabetologie, Kantonsspital Frauenfeld, Frauenfeld, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wiesli", 
        "givenName": "Peter", 
        "id": "sg:person.01010671162.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010671162.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "FMH Endokrinologie/Diabetologie, Hormonpraxis Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schories", 
        "givenName": "Marcus", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/dom.12626", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001152639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.26.11.3080", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001311481"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc14-0006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005077665"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc14-0990", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005726723"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.1994.tb05705.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013573296"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc12-0413", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013892720"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00592-016-0862-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016244112", 
          "https://doi.org/10.1007/s00592-016-0862-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-5491.2012.03605.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019396014"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmsb1609216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021917470"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc13-0331", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024715393"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12415", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029208093"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2013.281053", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031488893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12689", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034145713"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/03007995.2016.1150821", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035543673"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12532", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037086145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc16-1974", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091190806"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc16-2725", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091190807"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.13105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091414816"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.diabet.2017.10.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092779517"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.13199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099915500"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.diabet.2018.02.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101111685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.diabet.2018.02.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101111685"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmjdrc-2017-000454", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101152463"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/db18-1020-p", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105077608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/db18-1029-p", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105077617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/db18-1032-p", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105077622"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc18-0559", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106143792"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "INTRODUCTION: Insulin glargine 300\u00a0U/mL (Gla-300, Toujeo\u00ae) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100\u00a0U/mL (Gla-100) and insulin degludec (IDeg). These properties have been shown to translate into an effective HbA1c reduction with the advantage of a lower risk of hypoglycemia in randomized controlled trials of Gla-300 versus Gla-100. In this study, we assessed the effectiveness and safety of Gla-300 under real-world conditions in Switzerland.\nMETHODS: The prospective, observational, open-label, multicenter study TOP-2 explored the effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5-10%) on their previous basal insulin in Germany, Austria, and Switzerland. The primary endpoints were the percentages of patients achieving a fasting plasma glucose (FPG) of\u2009\u2264\u20096.1\u00a0mmol/L after 6 and 12\u00a0months. Secondary endpoints included changes in HbA1c, FPG, body weight, and insulin dose as well as hypoglycemia incidence and safety. Here we report the results for the Swiss patient cohort after 12\u00a0months of treatment with insulin glargine 300\u00a0U/mL.\nRESULTS: The 62 patients (33 men) had a mean age of 65\u00a0years, a mean diabetes duration of 14\u00a0years, a mean body mass index (BMI) of 31\u00a0kg/m2, and were mainly switched from Gla-100 (44%) to Gla-300. The most common concomitant oral anti-diabetes therapy was metformin (65%). The mean individual HbA1c target chosen by the investigators was 7.4%. After 12\u00a0months of therapy, Gla-300 significantly reduced mean HbA1c from 8.2% to 7.6% (p\u2009<\u20090.0001). Likewise, Gla-300 significantly reduced mean FPG from 9.1\u00a0mmol/L to 7.4\u00a0mmol/L (p\u2009<\u20090.0001). At study end, 32% of patients achieved FPG\u2009\u2264\u20096.1\u00a0mmol/L, 55% achieved FPG\u2009\u2264\u20097.2\u00a0mmol/L , and 57% achieved their individual HbA1c target. Gla-300 was uptitrated to a mean dose of 40 units per day. Symptomatic hypoglycemia incidence after 12\u00a0months was low at 9.7% and a rate of 0.23 events per patient year. Body weight remained stable and was not significantly altered during the study.\nCONCLUSION: Upon switching basaI insulin to Gla-300, overall glucose control significantly improved and glycemic targets were achieved with a low rate of hypoglycemia in T2D patients under real-world conditions in Switzerland.\nFUNDING: Sanofi-Aventis (Suisse) SA.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s13300-018-0518-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "name": "Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo\u00ae) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland", 
    "pagination": "2325-2334", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "230645a89078b2a23998e70ea0b9af81c1f3f464ba7e035755d28c003a93ff11"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30302721"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101539025"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-018-0518-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107493201"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-018-0518-x", 
      "https://app.dimensions.ai/details/publication/pub.1107493201"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T08:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000289_0000000289/records_95827_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs13300-018-0518-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0518-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0518-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0518-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0518-x'


 

This table displays all metadata directly associated to this object as RDF triples.

156 TRIPLES      21 PREDICATES      55 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-018-0518-x schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nc091564a29a04f93bc3f107d77d7a5c2
4 schema:citation sg:pub.10.1007/s00592-016-0862-0
5 https://doi.org/10.1001/jama.2013.281053
6 https://doi.org/10.1016/j.diabet.2017.10.001
7 https://doi.org/10.1016/j.diabet.2018.02.002
8 https://doi.org/10.1056/nejmsb1609216
9 https://doi.org/10.1111/dom.12415
10 https://doi.org/10.1111/dom.12532
11 https://doi.org/10.1111/dom.12626
12 https://doi.org/10.1111/dom.12689
13 https://doi.org/10.1111/dom.13105
14 https://doi.org/10.1111/dom.13199
15 https://doi.org/10.1111/j.1365-2125.1994.tb05705.x
16 https://doi.org/10.1111/j.1464-5491.2012.03605.x
17 https://doi.org/10.1136/bmjdrc-2017-000454
18 https://doi.org/10.1185/03007995.2016.1150821
19 https://doi.org/10.2337/db18-1020-p
20 https://doi.org/10.2337/db18-1029-p
21 https://doi.org/10.2337/db18-1032-p
22 https://doi.org/10.2337/dc12-0413
23 https://doi.org/10.2337/dc13-0331
24 https://doi.org/10.2337/dc14-0006
25 https://doi.org/10.2337/dc14-0990
26 https://doi.org/10.2337/dc16-1974
27 https://doi.org/10.2337/dc16-2725
28 https://doi.org/10.2337/dc18-0559
29 https://doi.org/10.2337/diacare.26.11.3080
30 schema:datePublished 2018-12
31 schema:datePublishedReg 2018-12-01
32 schema:description INTRODUCTION: Insulin glargine 300 U/mL (Gla-300, Toujeo®) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). These properties have been shown to translate into an effective HbA1c reduction with the advantage of a lower risk of hypoglycemia in randomized controlled trials of Gla-300 versus Gla-100. In this study, we assessed the effectiveness and safety of Gla-300 under real-world conditions in Switzerland. METHODS: The prospective, observational, open-label, multicenter study TOP-2 explored the effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5-10%) on their previous basal insulin in Germany, Austria, and Switzerland. The primary endpoints were the percentages of patients achieving a fasting plasma glucose (FPG) of ≤ 6.1 mmol/L after 6 and 12 months. Secondary endpoints included changes in HbA1c, FPG, body weight, and insulin dose as well as hypoglycemia incidence and safety. Here we report the results for the Swiss patient cohort after 12 months of treatment with insulin glargine 300 U/mL. RESULTS: The 62 patients (33 men) had a mean age of 65 years, a mean diabetes duration of 14 years, a mean body mass index (BMI) of 31 kg/m2, and were mainly switched from Gla-100 (44%) to Gla-300. The most common concomitant oral anti-diabetes therapy was metformin (65%). The mean individual HbA1c target chosen by the investigators was 7.4%. After 12 months of therapy, Gla-300 significantly reduced mean HbA1c from 8.2% to 7.6% (p < 0.0001). Likewise, Gla-300 significantly reduced mean FPG from 9.1 mmol/L to 7.4 mmol/L (p < 0.0001). At study end, 32% of patients achieved FPG ≤ 6.1 mmol/L, 55% achieved FPG ≤ 7.2 mmol/L , and 57% achieved their individual HbA1c target. Gla-300 was uptitrated to a mean dose of 40 units per day. Symptomatic hypoglycemia incidence after 12 months was low at 9.7% and a rate of 0.23 events per patient year. Body weight remained stable and was not significantly altered during the study. CONCLUSION: Upon switching basaI insulin to Gla-300, overall glucose control significantly improved and glycemic targets were achieved with a low rate of hypoglycemia in T2D patients under real-world conditions in Switzerland. FUNDING: Sanofi-Aventis (Suisse) SA.
33 schema:genre research_article
34 schema:inLanguage en
35 schema:isAccessibleForFree true
36 schema:isPartOf Nbdb8b7f6e4ef429fad0ff8e1fa5543b3
37 Nfdd3ed955d704489b376b410b6dc8c01
38 sg:journal.1044057
39 schema:name Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland
40 schema:pagination 2325-2334
41 schema:productId N2a8bb94a767349e992c8091de5c4f98c
42 N52d60a8604df4826adf05510dd93f9ec
43 N55d95da1b6794c62850a15a34c121998
44 N984457d97ebd463c9714b4fdbddb276f
45 Nd276b2ddfe104f81972cab225e6cc847
46 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107493201
47 https://doi.org/10.1007/s13300-018-0518-x
48 schema:sdDatePublished 2019-04-11T08:20
49 schema:sdLicense https://scigraph.springernature.com/explorer/license/
50 schema:sdPublisher N3cb81e940e384f5a9a8a2ce9dec0eac3
51 schema:url https://link.springer.com/10.1007%2Fs13300-018-0518-x
52 sgo:license sg:explorer/license/
53 sgo:sdDataset articles
54 rdf:type schema:ScholarlyArticle
55 N226b392901854760829c6cb11859c387 rdf:first Nd59f0b7949874454afa5d141eaaac56a
56 rdf:rest rdf:nil
57 N2a8bb94a767349e992c8091de5c4f98c schema:name doi
58 schema:value 10.1007/s13300-018-0518-x
59 rdf:type schema:PropertyValue
60 N3cb81e940e384f5a9a8a2ce9dec0eac3 schema:name Springer Nature - SN SciGraph project
61 rdf:type schema:Organization
62 N4a96c19ef30e4eb49c2cbd2fc562fcb2 schema:name FMH Endokrinologie/Diabetologie, Hormonpraxis Basel, Switzerland
63 rdf:type schema:Organization
64 N52d60a8604df4826adf05510dd93f9ec schema:name dimensions_id
65 schema:value pub.1107493201
66 rdf:type schema:PropertyValue
67 N55d95da1b6794c62850a15a34c121998 schema:name pubmed_id
68 schema:value 30302721
69 rdf:type schema:PropertyValue
70 N984457d97ebd463c9714b4fdbddb276f schema:name nlm_unique_id
71 schema:value 101539025
72 rdf:type schema:PropertyValue
73 Nbdb8b7f6e4ef429fad0ff8e1fa5543b3 schema:issueNumber 6
74 rdf:type schema:PublicationIssue
75 Nc091564a29a04f93bc3f107d77d7a5c2 rdf:first sg:person.01010671162.25
76 rdf:rest N226b392901854760829c6cb11859c387
77 Nd276b2ddfe104f81972cab225e6cc847 schema:name readcube_id
78 schema:value 230645a89078b2a23998e70ea0b9af81c1f3f464ba7e035755d28c003a93ff11
79 rdf:type schema:PropertyValue
80 Nd59f0b7949874454afa5d141eaaac56a schema:affiliation N4a96c19ef30e4eb49c2cbd2fc562fcb2
81 schema:familyName Schories
82 schema:givenName Marcus
83 rdf:type schema:Person
84 Nfdd3ed955d704489b376b410b6dc8c01 schema:volumeNumber 9
85 rdf:type schema:PublicationVolume
86 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
87 schema:name Medical and Health Sciences
88 rdf:type schema:DefinedTerm
89 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
90 schema:name Clinical Sciences
91 rdf:type schema:DefinedTerm
92 sg:journal.1044057 schema:issn 1869-6953
93 1869-6961
94 schema:name Diabetes Therapy
95 rdf:type schema:Periodical
96 sg:person.01010671162.25 schema:affiliation https://www.grid.ac/institutes/grid.459679.0
97 schema:familyName Wiesli
98 schema:givenName Peter
99 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010671162.25
100 rdf:type schema:Person
101 sg:pub.10.1007/s00592-016-0862-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016244112
102 https://doi.org/10.1007/s00592-016-0862-0
103 rdf:type schema:CreativeWork
104 https://doi.org/10.1001/jama.2013.281053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031488893
105 rdf:type schema:CreativeWork
106 https://doi.org/10.1016/j.diabet.2017.10.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092779517
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1016/j.diabet.2018.02.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101111685
109 rdf:type schema:CreativeWork
110 https://doi.org/10.1056/nejmsb1609216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021917470
111 rdf:type schema:CreativeWork
112 https://doi.org/10.1111/dom.12415 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029208093
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1111/dom.12532 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037086145
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1111/dom.12626 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001152639
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1111/dom.12689 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034145713
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1111/dom.13105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091414816
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1111/dom.13199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099915500
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1111/j.1365-2125.1994.tb05705.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1013573296
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1111/j.1464-5491.2012.03605.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019396014
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1136/bmjdrc-2017-000454 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101152463
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1185/03007995.2016.1150821 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035543673
131 rdf:type schema:CreativeWork
132 https://doi.org/10.2337/db18-1020-p schema:sameAs https://app.dimensions.ai/details/publication/pub.1105077608
133 rdf:type schema:CreativeWork
134 https://doi.org/10.2337/db18-1029-p schema:sameAs https://app.dimensions.ai/details/publication/pub.1105077617
135 rdf:type schema:CreativeWork
136 https://doi.org/10.2337/db18-1032-p schema:sameAs https://app.dimensions.ai/details/publication/pub.1105077622
137 rdf:type schema:CreativeWork
138 https://doi.org/10.2337/dc12-0413 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013892720
139 rdf:type schema:CreativeWork
140 https://doi.org/10.2337/dc13-0331 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024715393
141 rdf:type schema:CreativeWork
142 https://doi.org/10.2337/dc14-0006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005077665
143 rdf:type schema:CreativeWork
144 https://doi.org/10.2337/dc14-0990 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005726723
145 rdf:type schema:CreativeWork
146 https://doi.org/10.2337/dc16-1974 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091190806
147 rdf:type schema:CreativeWork
148 https://doi.org/10.2337/dc16-2725 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091190807
149 rdf:type schema:CreativeWork
150 https://doi.org/10.2337/dc18-0559 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106143792
151 rdf:type schema:CreativeWork
152 https://doi.org/10.2337/diacare.26.11.3080 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001311481
153 rdf:type schema:CreativeWork
154 https://www.grid.ac/institutes/grid.459679.0 schema:alternateName Kantonsspital Frauenfeld
155 schema:name FMH Endokrinologie/Diabetologie, Kantonsspital Frauenfeld, Frauenfeld, Switzerland
156 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...